한글목차

세계의 VNA 및 PACS(의료영상저장전송시스템) 시장 규모는 2025년 51억 달러에서 2030년까지 79억 2,000만 달러에 이를 것으로 예측되며, 예측 기간에 CAGR 9.2%의 성장이 전망됩니다.

의료 영상 데이터의 급증, 전사적 상호운용성 전환, 영상 워크플로우 최적화를 위한 벤더 중립적인 중앙 집중식 플랫폼에 대한 수요 증가 등이 시장 성장의 주요 요인으로 작용하고 있습니다. 또한, 의료의 디지털화를 위한 노력과 의료 정보 교환을 촉진하는 규제 프레임워크가 시장 성장을 더욱 촉진하고 있습니다. 그러나 높은 구현 비용과 데이터 마이그레이션에 따른 복잡성은 특히 중소규모의 의료기관이 첨단 VNA/PACS를 도입하는 데 있어 여전히 큰 장벽으로 작용하고 있습니다.

제품 유형별로는 멀티사이트 VNA 부문이 예측 기간 동안 가장 높은 성장률을 보일 것으로 예측됩니다.

의료 영상 솔루션에 대한 수요 증가의 주요 원인은 의료 시스템이 다양한 지리적 위치에서 영상 워크플로우를 최적화하기 위해 상호 운용성과 시설 간 데이터 통합을 중요시하게 되었기 때문입니다. 병원과 의료 시스템이 통합 네트워크로 통합됨에 따라 원활한 데이터 액세스와 공동 진단 작업을 촉진하기 위해 종합적인 영상 저장소를 구축하는 것이 필수적입니다. 또한, 코로나19 팬데믹으로 인해 강화된 원격 진단, 원격 진료 및 가상 진료 프레임워크로의 전환은 언제 어디서나 의료 영상에 안전하게 접근할 수 있는 확장 가능한 멀티사이트 VNA의 필요성을 강조하고 있습니다. 이러한 첨단 솔루션은 데이터 사일로를 해소하고 이미지 중복을 최소화할 뿐만 아니라, 다양한 진료과와 시설 간의 진료 조정을 강화하는 데 도움이 됩니다.

배포별로 보면, On-Premise 배포 부문이 2024년 가장 큰 시장 점유율을 차지했습니다.

의료 기관은 모니터링을 유지하고 장기적인 비용 예측 가능성을 확보하기 위해 인프라를 On-Premise에 구축하는 것을 선호하고 있습니다. 이러한 기관들은 보안과 성능 안정성을 우선시하고 있으며, 이는 자본 예산 편성 관행과도 일치합니다. 스토리지를 사내에서 관리함으로써 엄격한 데이터 거버넌스 표준을 준수하는 동시에 신뢰할 수 있는 이미징 성능을 일관되게 제공할 수 있습니다. 이 분야에서 중요한 고려 사항은 총소유비용(TCO)입니다. 클라우드 기반 솔루션은 일반적으로 민첩성이 높고 초기 투자 비용이 적게 드는 반면, On-Premise 구축은 특히 기존 IT 팀과 일정 수준의 이미징 수가 요구되는 기관의 경우 장기적인 투자 수익률(ROI)이 더 높은 경우가 많습니다. 또한, 하드웨어의 효율성이 향상됨에 따라 로컬 배포의 경제성과 안정성이 향상되고 있습니다.

지역별로는 아시아태평양이 2025-2030년 가장 높은 CAGR을 보일 것으로 예측됩니다.

아시아태평양 시장은 의료 영상 인프라에 대한 투자 증가, 의료 접근성 확대, 신흥 경제권 전반의 병원 시스템의 급속한 디지털화로 인해 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 인도, 중국, 동남아시아 국가들에서 영상 진단 기능이 강화되고 있으며, 의료 기관들은 임상 영상 및 관련 데이터를 관리하기 위해 중앙 집중식 상호 운용 가능한 솔루션을 찾고 있습니다. 동시에, 기술 발전과 클라우드 컴퓨팅의 확산으로 기업용 이미징 솔루션, 특히 VNA와 PACS는 다양한 규모의 의료기관에서 확장성과 비용 효율성이 향상되고 있습니다. 디지털 헬스 전략이 국가적 필수 사항으로 떠오르면서 영상 워크플로우 최적화, 방사선 데이터에 대한 원격 액세스 촉진, 시설 간 데이터 상호운용성 촉진에 대한 관심이 점점 더 높아지고 있습니다. 이러한 정책은 영상 정보의 통합적이고 원활한 관리를 지원하는 VNA-PACS 플랫폼이 제공하는 고유한 이점과 잘 부합합니다.

세계의 VNA 및 PACS 시장에 대해 조사 분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 조사 결과

• VNA 및 PACS 시장 개요
• 아시아태평양의 VNA 및 PACS 시장 : 제품 유형별, 국가별
• VNA 및 PACS 시장 : 지역적 성장 기회
• VNA 및 PACS 시장 : 지역 구성
• VNA 및 PACS 시장 : 선진국 시장과 신흥 국가 시장

제5장 시장 개요

• 서론
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 산업 동향
  • 클라우드 채택
  • AI와 ML의 통합
  • 밸류 기반 케어 모델
• 기술 분석
  • 주요 기술
  • 보완 기술
  • 인접 기술
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 밸류체인 분석
• 생태계 분석
• 투자 및 자금조달 시나리오
• Porter의 Five Forces 분석
• 주요 이해관계자와 구입 기준
• 주요 컨퍼런스 및 이벤트(2025년-2026년)
• 가격 분석
  • VNA 및 PACS 솔루션 평균 판매 가격 : 제품 유형별(2024년)
  • VNA 및 PACS 솔루션 평균 판매 가격 : 지역별(정성)
• 규제 분석
  • 규제기관, 정부기관, 기타 조직
  • 규제 구조
• 특허 분석
  • 인사이트 : 관할과 주요 신청자 분석
  • 주요 특허 리스트(2020년-2024년)
• 사례 연구 분석
• 미충족 요구와 최종사용자 기대
• 비즈니스 모델
  • 기업 라이선싱 모델
  • SaaS 모델
  • 종량 빌링 모델
  • 하이브리드 모델
• VNA 및 PACS 시장에 대한 미국 관세의 영향(2025년)
  • 서론
  • 주요 관세율
  • 가격 영향 분석
  • 국가/지역에 대한 영향
  • 최종 이용 산업에 대한 영향
  • 결론

제6장 VNA 및 PACS(의료영상저장전송시스템) 시장 : 모달리티별

• 서론
• CT
• 맘모그래피
• 초음파
• MRI
• X선
• PET

제7장 VNA 및 PACS(의료영상저장전송시스템) 시장 : 전개 모델별

• 서론
• On-Premise 전개 모델
• 클라우드 기반 전개 모델
• 하이브리드 전개 모델

제8장 VNA 및 PACS(의료영상저장전송시스템) 시장 : 제품 유형별

• 서론
• VNA
  • 부문 VNA
  • 복수 부문 VNA
  • 멀티 사이트 VNA
• PACS
  • 부문 PACS
  • 복수 부문 PACS
  • 멀티 사이트 PACS

제9장 VNA 및 PACS(의료영상저장전송시스템) 시장 : 벤더 유형별

• 서론
• 독립계 벤더
• 써드파티 벤더

제10장 VNA 및 PACS(의료영상저장전송시스템) 시장 : 용도별

• 서론
• 심장
• 정형외과
• 종양
• 신경
• 산부인과
• 기타 용도

제11장 VNA 및 PACS(의료영상저장전송시스템) 시장 : 최종사용자별

• 서론
• 병원 및 진료소
• 진단센터
• 외래수술센터(ASC)
• 기타 최종사용자

제12장 VNA 및 PACS(의료영상저장전송시스템) 시장 : 지역별

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 일본
  • 중국
  • 인도
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 중동 및 아프리카의 거시경제 전망
  • GCC 국가
  • 기타 중동 및 아프리카

제13장 경쟁 구도

• 서론
• 주요 시장 진출기업의 전략/강점
• 매출 분석(2020년-2024년)
• 시장 점유율 분석(2024년)
• 기업 평가 매트릭스 : 주요 기업(2024년)
• 기업 평가 매트릭스 : 스타트업/중소기업(2024년)
• 기업 평가와 재무 지표
  • 재무 지표
  • 기업 평가
• 브랜드/소프트웨어 비교
• 경쟁 시나리오

제14장 기업 개요

• 주요 기업
  • AGFA-GEVAERT GROUP
  • FUJIFILM HOLDINGS CORPORATION
  • SECTRA AB
  • GE HEALTHCARE
  • MERATIVE
  • KONINKLIJKE PHILIPS N.V.
  • CANON MEDICAL SYSTEMS CORPORATION
  • INTELERAD. INTELERAD.
  • PAXERAHEALTH
  • NOVARAD CORPORATION
  • HYLAND SOFTWARE, INC.
  • SIEMENS HEALTHINEERS AG
  • BRIDGEHEAD SOFTWARE LTD.
  • CANOPY PARTNERS
  • CRELIOHEALTH INC.
  • ASPYRA, LLC
  • POSTDICOM
  • MEDICASOFT
  • ESAOTE S.P.A.
  • VISUS HEALTH IT GMBH
• 기타 기업
  • ADVAHEALTH SOLUTIONS
  • SOFTTEAM SOLUTIONS PVT. LTD.
  • ARO SYSTEMS
  • CENTRAL DATA NETWORKS
  • ONEPACS
  • DEDALUS S.P.A.

제15장 부록

영문목차

The global VNA & PACS market is projected to reach USD 7.92 billion by 2030 from USD 5.10 billion in 2025, at a CAGR of 9.2% during the forecast period. Market expansion is largely fueled by the surging volume of medical imaging data, the transition towards enterprise-wide interoperability, and the increasing demand for centralized, vendor-neutral platforms designed to optimize imaging workflows. Additionally, initiatives aimed at healthcare digitization and regulatory frameworks promoting health information exchange are further catalyzing market growth. However, the high costs associated with implementation and the complexities related to data migration remain significant barriers to the adoption of advanced VNA and PACS, particularly for small to mid-sized healthcare organizations.

On the basis of product type, the multi-site VNA segment is expected to witness the highest growth rate during the forecast period.

Based on product type, the VNA & PACS market is segmented into VNA (further subsegmented into department, multi-department, and multi-site VNA) and PACS (further subsegmented into department, multi-department, and multi-site PACS). The multi-site VNA subsegment is expected to witness the fastest CAGR during the forecast period. The escalating demand for medical imaging solutions is primarily driven by the increasing emphasis of healthcare systems on interoperability and cross-institutional data integration to optimize imaging workflows across diverse geographical locations. As hospitals and health systems consolidate into integrated networks, the establishment of a comprehensive imaging repository has become essential for facilitating seamless data access and collaborative diagnostic efforts. Additionally, the transition towards remote diagnostics, teleconsultations, and virtual care frameworks-exacerbated by the COVID-19 pandemic-has underscored the imperative for scalable, multi-site VNAs that enable secure and anytime-anywhere access to medical imaging. These advanced solutions not only help dismantle data silos and minimize image duplication but also enhance care coordination across various departments and facilities.

On the basis of deployment, the on-premises deployment segment held the largest market share in 2024.

On the basis of deployment, the VNA & PACS market has been segmented into on-premises, cloud-based, and hybrid deployment. The on-premises deployment segment held the largest market share in 2024. Healthcare institutions are increasingly favoring on-premises deployment in infrastructure to maintain oversight and achieve long-term cost predictability, particularly those with substantial resources or large-scale operations. These organizations prioritize security and performance stability, which aligns well with capital budgeting practices. By managing storage internally, they ensure compliance with stringent data governance standards while consistently delivering reliable imaging performance. A critical consideration in this area is the total cost of ownership (TCO). Although cloud-based solutions typically offer greater agility and require a lower upfront investment, on-premises deployment often provides superior long-term return on investment (ROI), especially for institutions equipped with established IT teams and fixed imaging volume requirements. Furthermore, advancements in hardware efficiencies are making local deployments increasingly economical and dependable.

On the basis of region, the Asia Pacific is expected to witness the highest CAGR from 2025 to 2030.

On the basis of region, the VNA & PACS market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Among these, the Asia Pacific market is expected to witness the highest CAGR due to an increased investment in medical imaging infrastructure, expanding healthcare access, and the rapid digitization of hospital systems across emerging economies. Countries such as India, China, and various Southeast Asian nations are enhancing their diagnostic imaging capabilities, leading healthcare organizations to explore centralized and interoperable solutions for the management of clinical images and associated data. Concurrently, technological advancements and the increasing adoption of cloud computing are rendering enterprise imaging solutions-specifically VNA and PACS-more scalable and cost-efficient across institutions of varying sizes. As digital health strategies emerge as national imperatives, there is an intensified focus on optimizing imaging workflows, facilitating remote access to radiological data, and promoting cross-facility data interoperability. These objectives are well-aligned with the inherent advantages offered by VNA and PACS platforms, which support integrated and seamless management of imaging information.

The breakdown of primary participants is as mentioned below:

• By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
• By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
• By Region - North America: 32%, Europe: 30%, Asia Pacific: 25%, Middle East & Africa: 5%, Latin America: 5%

Key Players

The key players functioning in the VNA & PACS market include Hyland Software, Inc. (US), Agfa-Gevaert Group (Belgium), Intelerad Medical Systems Inc. (Canada), Canon Medical Systems Corporation (Japan), FUJIFILM Holdings Corporation (Japan), GE Healthcare (US), Merative (US), Sectra AB (Sweden), Siemens Healthcare Limited (Germany), BridgeHead Software Ltd. (UK), Canopy Partners. (US), Novarad Corporation (US), POSTDICOM (Netherlands), AdvaHealth Solutions Pte Ltd. (Singapore), CrelioHealth (India), Medicasoft (US), Esaote S.p.A. (Italy), PaxeraHealth (US), VISUS Health IT GmbH (Germany), ASPYRA, LLC (US), Dedalus S.p.A. (Italy), SoftTeam Solutions Pvt. Ltd. (India), ARO Systems (Australia), Central Data Networks (Australia), and ONEPACS (US).

Research Coverage:

The report analyses the VNA & PACS market to estimate the market size and future growth potential of various market segments based on product type, modality, deployment, vendor type, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report provides valuable insights for both established firms and emerging or smaller players, enabling them to accurately assess market dynamics. By leveraging the information presented, organizations can adopt various strategies outlined below to enhance their competitive positioning and increase market share..

This report provides insights on:

• Analysis of DROCs: Drivers [increasing investments in medical imaging technologies, growing demand for streamlined healthcare data management solutions, Integration of PACS/VNA with electronic medical records (EMRs)], restraints [increasing data security and privacy concerns, high initial investment, lack of standardized protocols and interoperability frameworks], opportunities [government initiatives to increase penetration of AI in medical imaging, Increasing medical imaging procedures and large imaging data silos, rapid uptake of big data in healthcare], and challenges [rising security concerns related to cloud-based image processing and analytics, data security issues] influencing the growth of the VNA & PACS market.
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product & service launches in the VNA & PACS market
• Market Development: Comprehensive information on the lucrative emerging markets, product type, modality, deployment, vendor type, application, end user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the VNA & PACS market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the VNA & PACS market, such as Agfa-Gevaert Group (Belgium), FUJIFILM Holdings Corporation (Japan), Sectra AB (Sweden), Merative (US), and GE Healthcare (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key primary insights
• 2.2 RESEARCH DESIGN
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 2.3.2 BOTTOM-UP APPROACH
  • 2.3.3 TOP-DOWN APPROACH
  • 2.3.4 TOP-DOWN APPROACH FOR PARENT MARKET ASSESSMENT
  • 2.3.5 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 OVERVIEW OF VNA & PACS MARKET
• 4.2 ASIA PACIFIC: VNA & PACS MARKET, BY PRODUCT TYPE AND COUNTRY
• 4.3 VNA & PACS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 VNA & PACS MARKET: REGIONAL MIX
• 4.5 VNA & PACS MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Heightened investments in medical imaging technologies
    • 5.2.1.2 Growing demand for streamlined healthcare data management solutions
    • 5.2.1.3 Integration of PACS/VNA with electronic medical records
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High initial investment for implementing VNA and PACS solutions
    • 5.2.2.2 Lack of standardized protocols and interoperability frameworks
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Favorable government initiatives for better penetration of AI in medical imaging
    • 5.2.3.2 Increasing medical imaging procedures and large imaging data silos
    • 5.2.3.3 Rapid uptake of big data in healthcare
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Rising security concerns related to cloud-based image processing and analytics
    • 5.2.4.2 Data security issues in healthcare settings
• 5.3 INDUSTRY TRENDS
  • 5.3.1 CLOUD ADOPTION
  • 5.3.2 AI AND ML INTEGRATION
  • 5.3.3 VALUE-BASED CARE MODELS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Digital imaging and communications in medicine (DICOM)
    • 5.4.1.2 Enterprise imaging solutions
    • 5.4.1.3 Cloud-based storage and services
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Image exchange networks
    • 5.4.2.2 Data analytics and business intelligence
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Health information exchange (HIE)
• 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 ROLE IN ECOSYSTEM
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9.2 BARGAINING POWER OF SUPPLIERS
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 THREAT OF NEW ENTRANTS
  • 5.9.5 THREAT OF SUBSTITUTES
• 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 KEY BUYING CRITERIA
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 PRICING ANALYSIS
  • 5.12.1 AVERAGE SELLING PRICE OF VNA & PACS SOLUTIONS, BY PRODUCT TYPE, 2024
  • 5.12.2 AVERAGE SELLING PRICE OF VNA & PACS SOLUTIONS, BY REGION (QUALITATIVE)
• 5.13 REGULATORY ANALYSIS
  • 5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13.2 REGULATORY FRAMEWORK
    • 5.13.2.1 North America
      • 5.13.2.1.1 US
    • 5.13.2.2 Europe
    • 5.13.2.3 Asia Pacific
      • 5.13.2.3.1 China
      • 5.13.2.3.2 Japan
      • 5.13.2.3.3 India
• 5.14 PATENT ANALYSIS
  • 5.14.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.14.2 LIST OF MAJOR PATENTS, 2020-2024
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 AMBRA HEALTH UTILIZED AWS CLOUD SERVICES TO PROPEL MEDICAL IMAGING PLATFORM GROWTH
  • 5.15.2 NHS TRUST ADOPTED INSTANT DATA ACCESS VNA TO ESTABLISH UNIFIED PLATFORM FOR DICOM IMAGE DATA STORAGE AND MANAGEMENT
• 5.16 UNMET NEEDS & END-USER EXPECTATIONS
  • 5.16.1 UNMET NEEDS
  • 5.16.2 END-USER EXPECTATIONS
• 5.17 BUSINESS MODELS
  • 5.17.1 ENTERPRISE LICENSING MODELS
  • 5.17.2 SOFTWARE-AS-A-SERVICE (SAAS) MODELS
  • 5.17.3 PAY-PER-USE MODELS
  • 5.17.4 HYBRID MODELS
• 5.18 IMPACT OF 2025 US TARIFF ON VNA & PACS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
      • 5.18.4.1.1 US
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals & clinics
    • 5.18.5.2 Diagnostics centers
    • 5.18.5.3 Ambulatory surgery centers
    • 5.18.5.4 Other end users
  • 5.18.6 CONCLUSION

6 VNA & PACS MARKET, BY MODALITY

• 6.1 INTRODUCTION
• 6.2 CT
  • 6.2.1 GROWING NEED FOR IMAGING MODALITIES IN MEDICAL FIELDS TO SUPPORT MARKET GROWTH
• 6.3 MAMMOGRAPHY
  • 6.3.1 RISING INCIDENCE OF BREAST CANCER TO PROPEL MARKET GROWTH
• 6.4 ULTRASOUND
  • 6.4.1 TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND DEVICES TO AID MARKET GROWTH
• 6.5 MRI
  • 6.5.1 COST-EFFECTIVENESS AND EASY AVAILABILITY IN SMALL HEALTHCARE FACILITIES TO FUEL MARKET ADOPTION
• 6.6 X-RAY
  • 6.6.1 DEVELOPMENTS IN X-RAY IMAGING TO BOOST ADOPTION OF VNA AND PACS SOLUTIONS
• 6.7 PET
  • 6.7.1 NEED FOR BETTER MANAGEMENT AND STORAGE OF LARGE DATA VOLUMES TO FAVOR MARKET GROWTH

7 VNA & PACS MARKET, BY DEPLOYMENT MODEL

• 7.1 INTRODUCTION
• 7.2 ON-PREMISES DEPLOYMENT MODELS
  • 7.2.1 BETTER CONTROL AND SECURITY FOR SENSITIVE PATIENT DATA TO AUGMENT MARKET GROWTH
• 7.3 CLOUD-BASED DEPLOYMENT MODELS
  • 7.3.1 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET
• 7.4 HYBRID DEPLOYMENT MODELS
  • 7.4.1 GREATER FLEXIBILITY, SCALABILITY, AND CONTROL OVER DATA MANAGEMENT STRATEGIES TO PROPEL MARKET GROWTH

8 VNA & PACS MARKET, BY PRODUCT TYPE

• 8.1 INTRODUCTION
• 8.2 VNA
  • 8.2.1 DEPARTMENT VNA
    • 8.2.1.1 Limitations in addressing scalability and interoperability across diverse departments to hinder market growth
  • 8.2.2 MULTI-DEPARTMENT VNA
    • 8.2.2.1 Multi-department VNA to streamline data management processes and reduce redundancies
  • 8.2.3 MULTI-SITE VNA
    • 8.2.3.1 Multi-site VNA to provide centralized repository for managing medical data and standardizing medical records
• 8.3 PACS
  • 8.3.1 DEPARTMENT PACS
    • 8.3.1.1 Need for better medical imaging data storage to aid market growth
  • 8.3.2 MULTI-DEPARTMENT PACS
    • 8.3.2.1 Technological advancements in multi-department PACS to improve image retrieval speed and ensure data integrity
  • 8.3.3 MULTI-SITE PACS
    • 8.3.3.1 Advancements in cloud-based PACS solutions to propel market growth

9 VNA & PACS MARKET, BY VENDOR TYPE

• 9.1 INTRODUCTION
• 9.2 INDEPENDENT VENDORS
  • 9.2.1 INCREASED FLEXIBILITY, BETTER INTEROPERABILITY, AND IMPROVED SOLUTIONS TO DRIVE MARKET
• 9.3 THIRD-PARTY VENDORS
  • 9.3.1 NEED FOR INNOVATIVE SOLUTIONS TO DRIVE THIRD-PARTY VENDOR PRESENCE

10 VNA & PACS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 CARDIOLOGY
  • 10.2.1 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
• 10.3 ORTHOPEDIC
  • 10.3.1 GROWING VOLUME AND COMPLEXITY OF ORTHOPEDIC MEDICAL IMAGING SCANS TO PROPEL MARKET GROWTH
• 10.4 ONCOLOGY
  • 10.4.1 RISING NUMBER OF CANCER CASES TO DRIVE USE OF VNA AND PACS SOLUTIONS FOR ONCOLOGY
• 10.5 NEUROLOGY
  • 10.5.1 INCREASING DEMAND FOR ADVANCED NEUROLOGICAL IMAGING TECHNOLOGIES TO SPUR GROWTH
• 10.6 OBSTETRICS & GYNECOLOGY
  • 10.6.1 USE OF 3D AND 4D IMAGING FOR MONITORING FETUS GROWTH AND DIAGNOSING HIGH-RISK PREGNANCIES TO DRIVE MARKET
• 10.7 OTHER APPLICATIONS

11 VNA & PACS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITALS & CLINICS
  • 11.2.1 NEED TO IMPROVE PROFITABILITY OF HEALTHCARE SERVICES TO DRIVE USE OF HCIT IN HOSPITALS
• 11.3 DIAGNOSTIC CENTERS
  • 11.3.1 LACK OF ADVANCED IMAGING MODALITIES IN SMALL AND MID-SCALE HOSPITALS TO AUGMENT MARKET GROWTH
• 11.4 AMBULATORY SURGERY CENTERS
  • 11.4.1 INCREASING NUMBER OF INTERVENTIONAL IMAGING PROCEDURES TO SUPPORT MARKET GROWTH
• 11.5 OTHER END USERS

12 VNA & PACS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 US to dominate global VNA & PACS market during study period
  • 12.2.3 CANADA
    • 12.2.3.1 Rising cases of end-stage kidney diseases to propel market growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Increasing number of MRI units and diagnostic imaging centers to drive market
  • 12.3.3 UK
    • 12.3.3.1 Rising funding and investments in diagnostic imaging to support market growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Rising target patient population and increasing government-funded investments to fuel uptake of VNA and PACS solutions
  • 12.3.5 ITALY
    • 12.3.5.1 Established healthcare infrastructure to aid market growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Growing access to advanced cancer diagnostics to propel market
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 JAPAN
    • 12.4.2.1 Presence of universal healthcare coverage to fuel market
  • 12.4.3 CHINA
    • 12.4.3.1 Strong government support for healthcare reforms and increased number of medical imaging procedures to drive market
  • 12.4.4 INDIA
    • 12.4.4.1 Improving healthcare infrastructure and increasing private-public partnerships to support market growth
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Presence of free and universal healthcare system to propel market growth
  • 12.5.3 MEXICO
    • 12.5.3.1 Rapid technological advancements in imaging solutions to support market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Technological integration to spur inclusivity, accessibility, affordability, and growth in healthcare sector
  • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VNA & PACS MARKET
• 13.3 REVENUE ANALYSIS, 2020-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Product type footprint
    • 13.5.5.4 Deployment model footprint
    • 13.5.5.5 End-user footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 13.6.5.1 Detailed list of key startups/SME players
    • 13.6.5.2 Competitive benchmarking of startups/SME players
• 13.7 COMPANY VALUATION & FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/SOFTWARE COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 OTHER DEVELOPMENTS

14 COMPANY PROFILES

• 14.1 KEY COMPANIES
  • 14.1.1 AGFA-GEVAERT GROUP
    • 14.1.1.1 Business overview
    • 14.1.1.2 Solutions offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 FUJIFILM HOLDINGS CORPORATION
    • 14.1.2.1 Business overview
    • 14.1.2.2 Solutions offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
      • 14.1.2.3.2 Other developments
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 SECTRA AB
    • 14.1.3.1 Business overview
    • 14.1.3.2 Solutions offered
    • 14.1.3.3 MnM view
      • 14.1.3.3.1 Right to win
      • 14.1.3.3.2 Strategic choices
      • 14.1.3.3.3 Weaknesses & competitive threats
  • 14.1.4 GE HEALTHCARE
    • 14.1.4.1 Business overview
    • 14.1.4.2 Solutions offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Right to win
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses & competitive threats
  • 14.1.5 MERATIVE
    • 14.1.5.1 Business overview
    • 14.1.5.2 Solutions offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses & competitive threats
  • 14.1.6 KONINKLIJKE PHILIPS N.V.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Solutions offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches
      • 14.1.6.3.2 Deals
  • 14.1.7 CANON MEDICAL SYSTEMS CORPORATION
    • 14.1.7.1 Business overview
    • 14.1.7.2 Solutions offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
      • 14.1.7.3.2 Expansions
  • 14.1.8 INTELERAD. INTELERAD.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Solutions offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
      • 14.1.8.3.2 Other developments
  • 14.1.9 PAXERAHEALTH
    • 14.1.9.1 Business overview
    • 14.1.9.2 Solutions offered
  • 14.1.10 NOVARAD CORPORATION
    • 14.1.10.1 Business overview
    • 14.1.10.2 Solutions offered
  • 14.1.11 HYLAND SOFTWARE, INC.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Solutions offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
  • 14.1.12 SIEMENS HEALTHINEERS AG
    • 14.1.12.1 Business overview
    • 14.1.12.2 Solutions offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
  • 14.1.13 BRIDGEHEAD SOFTWARE LTD.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Solutions offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Deals
  • 14.1.14 CANOPY PARTNERS
    • 14.1.14.1 Business overview
    • 14.1.14.2 Solutions offered
  • 14.1.15 CRELIOHEALTH INC.
    • 14.1.15.1 Business overview
    • 14.1.15.2 Solutions offered
  • 14.1.16 ASPYRA, LLC
    • 14.1.16.1 Business overview
    • 14.1.16.2 Solutions offered
  • 14.1.17 POSTDICOM
    • 14.1.17.1 Business overview
    • 14.1.17.2 Solutions offered
  • 14.1.18 MEDICASOFT
    • 14.1.18.1 Business overview
    • 14.1.18.2 Solutions offered
  • 14.1.19 ESAOTE S.P.A.
    • 14.1.19.1 Business overview
    • 14.1.19.2 Solutions offered
    • 14.1.19.3 Recent developments
      • 14.1.19.3.1 Product launches
  • 14.1.20 VISUS HEALTH IT GMBH
    • 14.1.20.1 Business overview
    • 14.1.20.2 Solutions offered
• 14.2 OTHER PLAYERS
  • 14.2.1 ADVAHEALTH SOLUTIONS
  • 14.2.2 SOFTTEAM SOLUTIONS PVT. LTD.
  • 14.2.3 ARO SYSTEMS
  • 14.2.4 CENTRAL DATA NETWORKS
  • 14.2.5 ONEPACS
  • 14.2.6 DEDALUS S.P.A.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS